The effect of propranolol on the prevention of ventricular tachycardia/fibrillation (VTNF) due to acute coronary ischaemia was studied in dogs. A series of propranolol-polymer controlled release matrices in slab configuration using various polyurethanes and a polyurethane-silicone rubber copolymer were formulated and characterized.
The effect of propranolol on the prevention of ventricular tachycardia/fibrillation (VTNF) due to acute coronary ischaemia was studied in dogs. A series of propranolol-polymer controlled release matrices in slab configuration using various polyurethanes and a polyurethane-silicone rubber copolymer were formulated and characterized.
In general, drug release in vitro occurred with an initial burst phase followed by an exponentially declining delivery rate; the silicone rubber containing copolymer preparation had more sustained release properties than did pure polyurethane matrices. In the animal studies, dogs underwent Shourly 10 min complete occlusions of the left anterior descending coronary artery (LAD), followed by 50 min normal perfusion. During non-drug occlusions VT occurred at a frequency of 1.22 -t 0.12 episodeslmin. A propranolol-polyurethane matrix (30% w/w, 26-42 mg) was placed on the ischaemic zone of the left ventricular epicardium immediately after the fifth occlusion. After an hour of drug delivery a sixth occlusion took place. The number of arrhythmia episodes both before and after drug were quantified and compared. The time to ventricular fibrillation (when present) and the mean blood pressure were also assessed. The drug patch delivered propranolol at a dose of 140 + 45 pglkg by the conclusion of the 1 h study period. Therapeutic drug levels were achieved in the peripheral blood samples (8.7-43.7 ng/ml) and were enhanced in coronary venous samples (360.9-556.2 ng/ml). Reduction of blood pressure and proarrhythmic events following epicardial controlled release propranolol administration were noted but were not statistically significant. Arrhythmia episodes before and after propranolol were not found to be significantly different (VT/min 1.02 k 0.31 and 1.22 +_ 0.12). The occlusion time until VF occurred was also not significantly different before versus after propranolol (t = 5.38 f 0.86 and 5.28 + 0.48 min). Therefore, despite attaining clinically therapeutic plasma levels, epicardial administration of propranolol was not found to be effective for the prevention of VTNF due to acute ischaemia. 
METHODS

Matrix formulation and in vitro release studies
Propranolol hydrochloride matrices were prepared by dissolving the drug in DMA and adding the polymer of interest already dissolved in DMA. The mixture was then poured into Teflon@' coated Petri dishes (10 cm diameter) and were dried in a vacuum oven at SO'C for 48 h. Propranolol polymer films were cut into 1 X 1 cm (200pm thick) squares for in vitro release, in triplicate, using 0.05 ITIM phosphate buffer under perfect sink conditions (20 ml volumes at pH 7.4, 37'C, 45 rev min-' changed daily). Propranolol release was quantitated by UV absorbance (&,, = 289 nm). The calibration curve was found to be linear in the range that was used (5-100 fl l/ml).
Stability test
To assess the stability of propranolol during the in vitro release study and storage periods, six solutions in a concentration range S-100 ng/ml were prepared, divided into groups and stored at 4 and 37'C. The UV readings of the freshly prepared solutions were compared with the UV readings of the same solutions after 1 and 7 d in the storage conditions.
Dog model of iscbaemic ventricular tacbycardia (VT) and ventricular fibrillation (VP)
Six male mongrel dogs (24-35 kg) underwent a left thoracotomy and pericardiotomy under pentobarbital anaesthesia.
A bipolar platinum electrode was placed on the left atria1 appendage and pacing was carried out during each study at 180 beatslmin using twice the diastolic capture threshold current. Surface electrodes and unipolar epicardial electrodes (on ischaemic and non-ischaemic zones of the left ventricle) were used for electrocardiogram recordings.
The blood pressure and the pacing electrode signal were also recorded. Each animal was subjected to &hourly 10 min complete occlusions of the LAD followed by 50 min of normal perfusion. Five replicate occlusions were carried out to assure the reproducibility of arrhythmias in each dog before therapy. This dog model is a modification of the method described by Elharrar et aLz7. In the current model, the hearts underwent a 10 min complete occlusion, as opposed to 8 min used by Elharrar et al.27. To normalize the data, the numbers of premature beats (PM), doublets (DB) and ventricular tachycardia (VT) episodes were calculated per minute. One of the common consequences of the repeated occlusions was ventricular fibrillation (VF) either during the occlusion or with reflow. In the event of fibrillation during an occlusion, the occluder was released and the dog resuscitated with a DC defibrillator. Arrhythmia episodes were counted during each occlusion period and during the intervening periods after the fourth and fifth occlusions.
Two consecutive premature beats were defined as a doublet while three or more were defined as ventricular tachycardia. Immediately after the fifth occlusion a propranolol patch was put on the LAD ischaemic zone. After the patch was in place for an hour the last 10 min occlusion was carried out. Blood samples were collected from the femoral and regional coronary veins every 10 min during the drug study period. Before storage at -20°C ascorbic acid (to a 5 mg/ml concentration) was added to the separated plasma to prevent propranolol oxidation".
Blood samples analysis
Peripheral and coronary venous propranolol levels were measured using a modification of an HPLC method that was described by Abdel-Hamid'*.
To a 1 ml aliquot of thawed peripheral plasma samples 100~1 of internal standard solution (Quinidine, 10 pg/ml), 1 ml of a sodium hydroxide soIution (1.0 M), 1 ml of water and 5 ml ether were added. After vortexing for 30 s and centrifuging for 10 min at 1800 rev min-' the aqueous layer was frozen over an isopropranol-dry ice bath and the ethereal phase was separated.
Then 200~1 0.1% phosphoric acid containing 5 mg/ml ascorbic acid were added to the ethereal phase, mixed, centrifuged and frozen. After discarding the ethereal layer the frozen pellets were thawed and 50 ~1 were injected into the HPLC. From the thawed coronary plasma only 0.5 ml aliquots were taken and NaOH (0.25 ml) and water (0.25 ml) were added. A calibration curve was prepared in 1 ml blank dog plasma containing 5 mg/ml ascorbic acid and was found to be linear in the range that was checked (lo-300 @/ml).
Residual matrix drug detection
Retrieved propranolol hydrochloride matrices in MPU-5 were extracted with methanol in a Soxhlet apparatus (Fisher Scientific). The extracts were analysed by HPLC (see later) and the net in viva release was calculated.
HPLC conditions
An isocratic separation was achieved as follows: the mobile phase was prepared by combining 56 ml phosphoric acid solution (0.02 M, pH 4) with 28ml of acetonitrile and 18 ml of methanol'*. The flow rate was 1 ml/min. A combination of 212 nm excitation filter and 340 nm emission filter were used for fluorescence detection. These conditions were used for quantitation of both the residual matrix propranolol after application and the blood samples.
RESULTS
In vitro release
Propranolol was previously foundz9 to be unstable at alkaline pH. To be certain that propranolol was stable during the release study at 37'C and during storage at 4°C the slopes of the calibration curves were compared after storage at each temperature.
The slope of the 'freshly prepared' calibration curve was not found to be significantly different from the slopes of the calibration curves of the solutions stored at 37 and 4°C after 1 d (y = 1.88 X 10~'x, 1.87 X lO%,
X lo-'x)
or 7 d (y = 1.86 X lo-'x, 2.03 X lo-%, 1.89 X lo-'x).
The release rates of propranolol from four different formulations were quantified and compared up to 10 d [ Figure 2 ). While the polyurethane preparations were releasing most of the drug during the first day, the copolymer matrix released only about 15% of its content over 10 d. When comparing the release up to 60 min, which was the duration of the in viva release up to the drug test occlusion it was found that the matrix that contained 30% propranolol hydrochloride in MPU-5 released 88.5 f 4.4% (mean+SD).
However, the 20% Since the amount of drug released from the 30% MPU-5 matrices was significantly greater than the amount released from the 20% preparations in MPU-5 and Biomer ft = 8.36, P = 0.001 and t = 6.81, P = 0.002 respectively) the matrix that contained 30% propranolol in MPU-5 was used for the in viva studies.
Arrh~hmia experiments
Dose
Following in vivo release (70 min) in the dogs, the drug matrices were extracted for residual propranolol content. It was found that 140 + 45 ,ug/kg of propranolol were delivered. Table 3 and Figure 2 . To examine the p~~h~hrnic effect of propranolol, the interval following the fourth occlusion, before the drug matrix was sewn on, and the interval after the fifth occlusion, following the matrix placement, were compared. Although the frequency of PM beats, DB and VT per min was greater during the hour after propranolol was administered to the heart compared to the control the differences were not significant statistically (P > 0.5, Student's t test). Propranolol also tended to reduce the mean blood pressure:
Ucclusion experjmen fs
the reduction was also not significant statistically (P > 0.5) compared to control. In addition, propranolol did not influence the onset of ventricular fibrillation.
Peripheral versus coronary blood levels following epicardial propranolol
Peripheral propranolol levels ranged from 8.7 to 43.7 nglml, while simultaneous coronary blood levels were significantly elevated (P < 0.001) compared with peripheral levels, and ranged from 360.6 to 556.2 rig/ml (Figure 3) , emphasizing the enhanced regional nature of epicardial controlled release therapy.
DISCUSSION
In the present study the in vitro release rate was found to be influenced by the nature of the polymer in which the drug was compounded.
The release rate from MPU-5, the most hydrophilic polymer used in our investigation, was significantly higher than the release rate from the other polyurethane studied, Biomer< which is relatively less hydrophilic than MPU-5. Furthermore the release rate of propranolol from the copolymer 6605-41 which was the least hydrophilic polymer investigated, since it is a polyurethane-silicone rubber, was more sustained than noted with MPU-5 or Biomer. The same trend was previously found3* for the release of FeCl, and Al(NO,), from Biomer and the copolymer 6605-41. The ability of these various polymer matrices to deliver a range of antiarrhythmic drug doses over prolonged periods of time is of particular importance;
for an acute arrhythmia a higher dose for a short period of time might be needed, while for maintenance of an inhibitory drug level for chronic arrhythmia therapy a lower dose over a long period of time might be needed.
The propranolol coronary blood levels were also shown to be up to 50 times greater than the peripheral levels. This result emphasizes the propensity for epicardial controlled release to achieve regionally high drug levels while minimizing the magnitude of systemic blood levels. The same phenomenon was demonstrated when either lidocaineg or procainamide" were administered to the heart by controlled release matrices. Plasma propranolol levels of up to 1000 nglml may be required to control resistant ventricular arrhythmias based on clinical results*. However, only 25% of the usual antiarrhythmic dose, 140 ,~~g/kg, was needed to achieve a nearly maximal therapeutic level in the coronary blood in the present study. Also, according to our results, when propranolol was given locally the peripheral drug levels were within the low end of the therapeutic range for L l-
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Frequency of arrhythmia episodes with and without Figure 2 propranorol during occlusion and reflow. Isolated premature beats (Ii), doublets (El), ventricular tachycardia (W). Although propranolol epicardial administration resulted in significantly higher blood levels in the heart compared with the peripheral blood, no significant antiarrhythmic effect was demonstrated. Furthermore, peripheral plasmapropranolol levels were also in the therapeutic range relative to clinical data concerning both arrhythmia therapy and hypertensions20-22~ 31. Prior animal and clinical studies have also demonstrated that systemic propranolol reduces the occurrence of ventricular arrhythmias due to myocardial ischaemia20-22~ 24-26 or infarctionl* 43 ', I78 ". Furthermore, systemic administration of propranolol by others has been effective in dog models of ischaemia comparable to ours24-26 and also infarctionrelated arrhythmias using net total dosages comparable to those used in the present study". These prior studies cannot be viewed as providing systemic drug administration of relevance for the present experiments. Thus, additional drug protocols in the present series of studies could have compared an array of systemic dosages of propranolol to the epicardial results. However, the lack of any antiarrhythmia activity with epicardial controlled release compared to non-drug coronary occlusions, despite near maximal coronary venous drug concentrations, and systemic hypotension obviates the usefulness of further studies along these lines. Furthermore, a relevant systemic dose for comparisons with the epicardial studies might have involved giving the same dose administered by the matrix intravenously over 1 h, or administering an appropriate intravenous dose based on pharmacokinetic parameters to achieve a systemic or coronary propranolol level identical to that achieved with epicardial administration.
Other treatment groups could also have considered regional intracoronary injection of propranolol or coronary venous retroperfusion, again to obtain coronary venous plasma levels identical to those achieved with a matrix. These other administration variations were beyond the scope of this study but may be worth further consideration.
In addition the present results suggest that while systemic P-blockade may be effective for ventricular arrhythmias this is likely be due to central effects rather than directly influencing cardiac /I-adrenergic activity. Alternatively, D-propranolol for suppression of ventricular arrhythmias in man has recently been shown to be as effective as the racemic preparation3', thereby demonstrating that propranolol's efficacy for ventricular arrhythmias may not be entirely related to its p -blocking. 
